Skip to main content
SpringerLink
Log in

Histone Deacetylase Inhibitors in Multiple Myeloma

  • Chapter
Myeloma Therapy

Part of the book series: Contemporary Hematology ((CH))

  • 566 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Verdin, E., Dequiedt, F., and Kasler, H. G. Class II histone deacetylases: Versatile regulators. Trends Genet 19: 286–293, 2003.

    Article  PubMed  CAS  Google Scholar 

  2. Minucci, S. and Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer, 6: 38–51, 2006.

    Article  PubMed  CAS  Google Scholar 

  3. Bolden, J. E., Peart, M. J., and Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov, 5: 769–784, 2006.

    Article  PubMed  CAS  Google Scholar 

  4. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A.., Marks, P. A., Breslow, R., and Pavletich, N. P., Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401: 188–1893, 1999.

    Article  PubMed  CAS  Google Scholar 

  5. Marks, P. A. and Jiang, X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle, 4: 549–551, 2005.

    Article  PubMed  CAS  Google Scholar 

  6. Marks, P. A. and Dokmanovic, M. Histone deacetylase inhibitors: Discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497–1511, 2005.

    Article  PubMed  CAS  Google Scholar 

  7. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr., and Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature, 391: 811–814, 1998.

    Article  PubMed  CAS  Google Scholar 

  8. Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., and Kelly, W. K. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer, 1: 194–202, 2001.

    Article  PubMed  CAS  Google Scholar 

  9. Mitsiades, N., Mitsiades, C. S., Richardson, P. G., McMullan, C., Poulaki, V., Fanourakis, G., Schlossman, R., Chauhan, D., Munshi, N. C., Hideshima, T., Richon, V. M., Marks, P. A., and Anderson, K. C. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood, 101: 4055–4062, 2003.

    Article  PubMed  CAS  Google Scholar 

  10. Sowa, Y., Orita, T., Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H., and Sakai, T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142–150, 1997.

    Article  PubMed  CAS  Google Scholar 

  11. Archer, S. Y., Meng, S., Shei, A., and Hodin, R. A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA, 95: 6791–6796, 1998.

    Article  PubMed  CAS  Google Scholar 

  12. Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V., and Bates, S. E. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83: 817–825, 2000.

    Article  PubMed  CAS  Google Scholar 

  13. Burgess, A. J., Pavey, S., Warrener, R., Hunter, L. J., Piva, T. J., Musgrove, E. A., Saunders, N., Parsons, P. G., and Gabrielli, B. G. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol, 60: 828–837, 2001.

    PubMed  CAS  Google Scholar 

  14. Qian, D. Z., Wang, X., Kachhap, S. K., Kato, Y., Wei, Y., Zhang, L., Atadja, P., and Pili, R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res, 64: 6626–6634, 2004.

    Article  PubMed  CAS  Google Scholar 

  15. Huang, L., Sowa, Y., Sakai, T., and Pardee, A. B. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoy-lanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene, 19: 5712–5719, 2000.

    Article  PubMed  CAS  Google Scholar 

  16. Richon, V. M., Sandhoff, T. W., Rifkind, R. A., and Marks, P. A. Histone deacety-lase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97: 10014–10019, 2000.

    Article  PubMed  CAS  Google Scholar 

  17. Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Richon, V. M., Marks, P. A., and Anderson, K. C. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA 101: 540–545, 2004.

    Article  PubMed  CAS  Google Scholar 

  18. Fandy, T. E., Shankar, S., Ross, D. D., Sausville, E., and Srivastava, R. K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia, 7: 646–657, 2005.

    Article  PubMed  CAS  Google Scholar 

  19. Kelly, W. K., Richon, V. M., O'Connor, O., Curley, T., MacGregor-Curtelli, B., Tong, W., Klang, M., Schwartz, L., Richardson, S., Rosa, E., Drobnjak, M., Cordon-Cordo, C., Chiao, J. H., Rifkind, R., Marks, P. A., and Scher, H. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578–3588, 2003.

    PubMed  CAS  Google Scholar 

  20. Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., Richardson, S., Chu, E., Olgac, S., Marks, P. A., Scher, H., and Richon, V. M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol, 23: 3923–3931, 2005.

    Article  PubMed  CAS  Google Scholar 

  21. Krug, L. M., Curley, T., Schwartz, L., Richardson, S., Marks, P., Chiao, J., and Kelly, W. K. Potential role of histone deacetylase inhibitors in mesothelioma: Clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer, 7: 257–261, 2006.

    Article  PubMed  Google Scholar 

  22. Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., and Frankel, S. R. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 109: 31–39, 2007.

    Article  PubMed  CAS  Google Scholar 

  23. Remiszewski, S. W., Sambucetti, L. C., Bair, K. W., Bontempo, J., Cesarz, D., Chandramouli, N., Chen, R., Cheung, M., Cornell-Kennon, S., Dean, K., Diamantidis, G., France, D., Green, M. A., Howell, K. L., Kashi, R., Kwon P Lassota, P., Martin, M. S., Mou, Y., Perez, L. B., Sharma, S., Smith, T., Sorensen, E., Taplin, F., Trogani, N., Versace, R., Walker, H., Weltchek-Engler S Wood, A., Wu, A., and Atadja, P. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)eth yl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 46: 4609–4624, 2003.

    Article  PubMed  CAS  Google Scholar 

  24. Atadja, P., Gao, L., Kwon, P., Trogani, N., Walker, H., Hsu, M., Yeleswarapu L Chandramouli, N., Perez, L., Versace, R., Wu, A., Sambucetti, L., Lassota P Cohen, D., Bair, K., Wood, A., and Remiszewski, S. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res, 64: 689–695, 2004.

    Article  PubMed  CAS  Google Scholar 

  25. Fiskus, W., Pranpat, M., Balasis, M., Herger, B., Rao, R., Chinnaiyan, A., Atadja, P., and Bhalla, K. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther, 5: 3096–3104, 2006.

    Article  PubMed  CAS  Google Scholar 

  26. Guo, F., Sigua, C., Tao, J., Bali, P., George, P., Li, Y., Wittmann, S., Moscinski, L., Atadja, P., and Bhalla, K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res, 64: 2580–2589, 2004.

    Article  PubMed  CAS  Google Scholar 

  27. Rosato, R. R., Maggio, S. C., Almenara, J. A., Payne, S. G., Atadja, P., Spiegel, S., Dent, P., and Grant, S. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol, 69: 216–225, 2006.

    PubMed  CAS  Google Scholar 

  28. Weisberg, E., Catley, L., Kujawa, J., Atadja, P., Remiszewski, S., Fuerst, P., Cavazza, C., Anderson, K., and Griffin, J. D. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia, 18: 1951–1963, 2004.

    Article  PubMed  CAS  Google Scholar 

  29. Catley, L., Weisberg, E., Tai, Y. T., Atadja, P., Remiszewski, S., Hideshima, T., Mitsiades, N., Shringarpure, R., LeBlanc, R., Chauhan, D., Munshi, N., Schlossman, R., Richardson, P., Griffin, J., and Anderson, K. C. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 102: 2615–2622, 2003.

    Article  PubMed  CAS  Google Scholar 

  30. George, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W., Guo, F., Sigua, C., Sondarva, G., Moscinski, L., Atadja, P., and Bhalla, K. Combination of the shistone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 105: 1768–1776, 2005.

    Article  PubMed  CAS  Google Scholar 

  31. Fiskus, W., Pranpat, M., Bali, P., Balasis, M., Kumaraswamy, S., Boyapalle, S., Rocha, K., Wu, J., Giles, F., Manley, P. W., Atadja, P., and Bhalla, K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood, 108: 645–652, 2006.

    Article  PubMed  CAS  Google Scholar 

  32. Geng, L., Cuneo, K. C., Fu, A., Tu, T., Atadja, P. W., and Hallahan, D. E. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res, 66: 11298–11304, 2006.

    Article  PubMed  CAS  Google Scholar 

  33. Yu, C., Friday, B. B., Lai, J. P., McCollum, A., Atadja, P., Roberts, L. R., and Adjei, A. A. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res 13: 1140–1148, 2007.

    Article  PubMed  CAS  Google Scholar 

  34. Qian, D. Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H. M., Salumbides, B., Sanni, T., Atadja, P., and Pili, R. Targeting tumor angiogenesis with histone deacety-lase inhibitors: The hydroxamic acid derivative LBH589. Clin Cancer Re s, 12: 634–642, 2006.

    Article  PubMed  CAS  Google Scholar 

  35. Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., and Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 100: 4389–4394, 2003.

    Article  PubMed  CAS  Google Scholar 

  36. Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., and Yao, T. P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell, 115: 727–738, 2003.

    Article  PubMed  CAS  Google Scholar 

  37. Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., Seto, E., and Bhalla, K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis of antileukemia activity of histone deacetylase inhibitors. J Biol Chem, 280: 26729–26734, 2005.

    Article  PubMed  CAS  Google Scholar 

  38. Maiso, P., Carvajal-Vergara, X., Ocio, E. M., Lopez-Perez, R., Mateo, G., Gutierrez, N., Atadja, P., Pandiella, A., and San Miguel, J. F. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res, 66: 5781–5789, 2006.

    Article  PubMed  CAS  Google Scholar 

  39. Catley, L., Weisberg, E., Kiziltepe, T., Tai, Y. T., Hideshima, T., Neri, P., Tassone, P., Atadja, P., Chauhan, D., Munshi, N. C., and Anderson, K. C. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood, 108: 3441–3449, 2006.

    Article  PubMed  CAS  Google Scholar 

  40. Furumai, R., Matsuyama, A., Kobashi, N., Lee, K. H., Nishiyama, M., Nakajima, H., Tanaka, A., Komatsu, Y., Nishino, N., Yoshida, M., and Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res, 62: 4916–4921, 2002.

    PubMed  CAS  Google Scholar 

  41. Rajgolikar, G., Chan, K. K., and Wang, H. C. Effects of a novel antitumor dep-sipeptide, FR901228, on human breast cancer cells. Breast Cancer Res Treat, 51: 29–38, 1998.

    Article  PubMed  CAS  Google Scholar 

  42. Doi, S., Soda, H., Oka, M., Tsurutani, J., Kitazaki, T., Nakamura, Y., Fukuda, M., Yamada, Y., Kamihira, S., and Kohno, S. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther, 3: 1397–1402, 2004.

    PubMed  CAS  Google Scholar 

  43. Zhang, Y., Adachi, M., Zhao, X., Kawamura, R., and Imai, K. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino-methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer, 110: 301–308, 2004.

    Article  PubMed  CAS  Google Scholar 

  44. Sakimura, R., Tanaka, K., Nakatani, F., Matsunobu, T., Li, X., Hanada, M., Okada, T., Nakamura, T., Matsumoto, Y., and Iwamoto, Y. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer, 116: 784–792, 2005.

    Article  PubMed  CAS  Google Scholar 

  45. Konstantinopoulos, P. A., Vandoros, G. P., and Papavassiliou, A. G. FK228 (depsipeptide): A HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol 58: 711–715, 2006.

    Article  PubMed  CAS  Google Scholar 

  46. Kano, Y., Akutsu, M., Tsunoda, S., Izumi, T., Kobayashi, H., Mano, H., and Furukawa, Y. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipep-tide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs, 25: 31–40, 2007.

    Article  PubMed  CAS  Google Scholar 

  47. Karam, J. A., Fan, J., Stanfield, J., Richer, E., Benaim, E. A., Frenkel, E., Antich, P., Sagalowsky, A. I., Mason, R. P., and Hsieh, J. T. The use of histone deacetylase inhibitor FK228 and DNA hyspomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer, 120: 1795–1802, 2007.

    Article  PubMed  CAS  Google Scholar 

  48. Khan, S. B., Maududi, T., Barton, K., Ayers, J., and Alkan, S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol, 125: 156–161, 2004.

    Article  PubMed  CAS  Google Scholar 

  49. Sandor, V., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R., Piekarz, R. L., Tucker, E., Figg, W. D., Chan, K. K., Goldspiel, B., Fojo, A. T., Balcerzak, S. P., and Bates, S. E. Phase I trial of the histone deacety-lase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718–728, 2002.

    PubMed  CAS  Google Scholar 

  50. Marshall, J. L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M. H., Figg, W. D., Wainer, I., Chaissang, C., Li, M. Z., and Hawkins, M. J. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2: 325–332, 2002.

    Article  PubMed  CAS  Google Scholar 

  51. Byrd, J. C., Marcucci, G., Parthun, M. R., Xiao, J. J., Klisovic, R. B., Moran, M., Lin, T. S., Liu, S., Sklenar, A. R., Davis, M. E., Lucas, D. M., Fischer, B., Shank, R., Tejaswi, S. L., Binkley, P., Wright, J., Chan, K. K., and Grever, M. R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 105: 959–967, 2005.

    Article  PubMed  CAS  Google Scholar 

  52. Robey, R. W., Zhan, Z., Piekarz, R. L., Kayastha, G. L., Fojo, T., and Bates, S. E. Increased MDR1 expression in normal and malignant peripheral blood mono-nuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 12: 1547–1555, 2006.

    Article  PubMed  CAS  Google Scholar 

  53. Stadler, W. M., Margolin, K., Ferber, S., McCulloch, W., and Thompson, J. A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer, 5: 57–60, 2006.

    Article  PubMed  CAS  Google Scholar 

  54. Plumb, J. A., Finn, P. W., Williams, R. J., Bandara, M. J., Romero, M. R., Watkins, C. J., La Thangue, N. B., and Brown, R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther, 2: 721–728, 2003.

    PubMed  CAS  Google Scholar 

  55. Qian, X., LaRochelle, W. J., Ara, G., Wu, F., Petersen, K. D., Thougaard, A., Sehested, M., Lichenstein, H. S., and Jeffers, M. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther, 5: 2086–2095, 2006.

    Article  PubMed  CAS  Google Scholar 

  56. Sullivan, D., Singhal, S., Schuster, M., Berenson, J., Gimsing, P., Wislö, F., Waage, A., Alsina, M., Gerwien, R., Clarke, A., Moller, K., and Ooi, C. E. A phase II study of PXD101 in advanced multiple myeloma. Blood, 108: 1023a, 2006.

    Google Scholar 

  57. Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., and Nakanishi, O. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem, 42: 3001–3003, 1999.

    Article  PubMed  CAS  Google Scholar 

  58. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27–275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96: 4592–4597, 1999.

    Article  PubMed  CAS  Google Scholar 

  59. Jaboin, J., Wild, J., Hamidi, H., Khanna, C., Kim, C. J., Robey, R., Bates, S. E., and Thiele, C. J. MS-27#x0026;ndash;275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62: 6108–6115, 2002.

    PubMed  CAS  Google Scholar 

  60. Maggio, S. C., Rosato, R. R., Kramer, L. B., Dai, Y., Rahmani, M., Paik, D. S., Czarnik, A. C., Payne, S. G., Spiegel, S., and Grant, S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64: 2590–2600, 2004.

    Article  PubMed  CAS  Google Scholar 

  61. Qian, D. Z., Wei, Y. F., Wang, X., Kato, Y., Cheng, L., and Pili, R. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate, 67: 1182–1193, 2007.

    Article  PubMed  CAS  Google Scholar 

  62. Lucas, D. M., Davis, M. E., Parthun, M. R., Mone, A. P., Kitada, S., Cunningham, K. D., Flax, E. L., Wickham, J., Reed, J. C., Byrd, J. C., and Grever, M. R. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia, 18: 1207–1214, 2004.

    Article  PubMed  CAS  Google Scholar 

  63. Miller, C. P., Ban, K., Dujka, M. E., McConkey, D. J., Munsell, M., Palladino, M., and Chandra, J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood, 110: 267–277, 2007.

    Article  PubMed  CAS  Google Scholar 

  64. Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J., Chung, E. J., Lee, M. J., Gore, S. D., Sausville, E. A., Zwiebel, J., and Karp, J. E. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood, 109: 2781–2790, 2007.

    PubMed  CAS  Google Scholar 

  65. Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., Melillo, G., Elsayed, Y., Monga, M., Kalnitskiy, M., Zwiebel, J., and Sausville, E. A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23: 3912–3922, 2005.

    Article  PubMed  CAS  Google Scholar 

  66. Garcia-Mata, R., Gao, Y. S., and Sztul, E. Hassles with taking out the garbage: Aggravating aggresomes. Traffic, 3: 388–396, 2002.

    Article  PubMed  CAS  Google Scholar 

  67. Hideshima, H., Bradner, J. E., Wong, J., D., C., Richardson, P., Schreiber, S. L., and Anderson, K. C. Small molecule inhibition of proteasome and aggresome function induces synergistic anti-tumor activity in multiple myeloma. Proc Natl Acad Sci USA, 102: 8567–8572, 2005.

    Article  PubMed  CAS  Google Scholar 

  68. Feng, R., Hager, J. H., Hassig, C. A., Scranton, S. A., Payne, J. E., Mapara, M. Y., Roodman, D., and Lentzsch, S. A novel, mercaptoketone-based HDAC inhibitor, KD5170 exerts marked inhibition of osteoclast formation and anti-Myeloma activity in vitro. Blood, 108: 991a, 2006.

    Google Scholar 

  69. Butler, L. M., Webb, Y., Agus, D. B., Higgins, B., Tolentino, T. R., Kutko, M. C., LaQuaglia, M. P., Drobnjak, M., Cordon-Cardo, C., Scher, H. I., Breslow, R., Richon, V. M., Rifkind, R. A., and Marks, P. A. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res, 7: 962–870, 2001.

    PubMed  CAS  Google Scholar 

  70. Kutko, M. C., Glick, R. D., Butler, L. M., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., and LaQuaglia, M. P. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res, 9: 5749–5755, 2003.

    PubMed  CAS  Google Scholar 

  71. LoRusso, P. M., Demchik, L., Foster, B., Knight, J., Bissery, M. C., Polin, L. M., Leopold, W. R., 3rd, and Corbett, T. H. Preclinical antitumor activity of CI-994. Invest New Drugs, 14: 349–356, 1996.

    Article  PubMed  CAS  Google Scholar 

  72. Graziano, M. J., Pilcher, G. D., Walsh, K. M., Kasali, O. B., and Radulovic, L. Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyldinaline), in rats and dogs. Invest New Drugs, 15: 295–310, 1997.

    Article  PubMed  CAS  Google Scholar 

  73. Piekarz, R. and Bates, S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10: 2289–2298, 2004.

    Article  PubMed  CAS  Google Scholar 

  74. Loprevite, M., Tiseo, M., Grossi, F., Scolaro, T., Semino, C., Pandolfi, A., Favoni, R., and Ardizzoni, A. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res, 15: 39–48, 2005.

    PubMed  CAS  Google Scholar 

  75. Yu, C., Rahmani, M., Conrad, D., Subler, M., Dent, P., and Grant, S. The protea-some inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood, 102: 3765–3774, 2003.

    Article  PubMed  CAS  Google Scholar 

  76. Denlinger, C. E., Keller, M. D., Mayo, M. W., Broad, R. M., and Jones, D. R. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg, 127: 1078–1086, 2004.

    Article  PubMed  CAS  Google Scholar 

  77. Sutheesophon, K., Kobayashi, Y., Takatoku, M. A., Ozawa, K., Kano, Y., Ishii, H., and Furukawa, Y. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol 115: 78–90, 2006.

    Article  PubMed  CAS  Google Scholar 

  78. Emanuele, S., Lauricella, M., Carlisi, D., Vassallo, B., D'Anneo, A., Di Fazio, P., Vento, R., and Tesoriere, G. SAHA induces apoptosis in hepatoma cells and syn-ergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis, 12(7): 1327–1338, 2007.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

    Teru Hideshima

Authors
  1. Teru Hideshima
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winship Cancer Institute, Emory University, B3307 Clifton Road, Atlanta, GA, 30322, USA

    Sagar Lonial MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hideshima, T. (2008). Histone Deacetylase Inhibitors in Multiple Myeloma. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-564-0_24

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-82-4

  • Online ISBN: 978-1-59745-564-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation